TRIPS Council to discuss IP and the public interest in the context of Covid-19
The search for new treatments and vaccines needed to respond to the Covid-19 outbreak has laid bare some key issues around intellectual property (IP)...
Wrapping Up 2017 – some noteworthy medicines law and policy events.
2017 was a significant year for access to medicines and other medicines policy related events. Here are a few highlights of the last 12...
Current drafts of the WHO Pandemic Accord lack a provision for access to knowhow/trade...
Negotiations are currently taking place at the World Health Organization (WHO) to conclude a new pandemic agreement by May 2024. The objective of the...
Written remarks submitted to the OHCHR following the Expert Workshop on the key challenges...
This blog was submitted by Dr. Katrina Perehudoff, Law Centre for Health and Rights at the University of Amsterdam, and Medicines Law & Policy,...
Cancer Drug Pricing on the World Health Organization’s Executive Board Agenda
On Thursday 24 January, the World Health Organization’s 144th Executive Board meeting will kick off in Geneva. One of the agenda items is access...
Wrapping up 2019 – Noteworthy Medicines Law and Policy Events
2019 had its share of noteworthy medicines law and policy events. It was also a year that saw eye-popping new levels of pharmaceutical pricing....
Dolutegravir Patent Licences Can Provide Access To All
This year the World Health Organization (WHO) added dolutegravir, an antiretroviral medicine for the treatment of HIV infection, to its Model List of Essential...
Covid-19 intellectual property pool gaining support
While drug and vaccine developers are working on tools to prevent and treat Covid- 19, here is a question the rest of us should...
Updated TRIPS Flexibilities Database
In January 2023, a number of cystic-fibrosis patient organisations asked the governments of Brazil, India, South Africa and Ukraine to invoke compulsory licensing and...
Gilead’s sofosbuvir patent in India – options for global access to new hepatitis C...
Earlier this month the US pharmaceutical company Gilead obtained a patent in India for sofosbuvir, part of a treatment of hepatitis C that became...